NMDA receptor hypofunction and schizophrenia

famotidine 20 mg twice a day as adjunctive therapy in an open-label study. SPEM were recorded for 60 seconds at baseline, after 3 weeks on famotidine, and 1 week after discontinuation, using a 0.4 Hz/10 degree amplitude stimulus. SPEM outcome measures included In signal/noise, saccade number, and percent error. We found no statistically significant effect of famotidine on any of our outcome measures, although there was considerable intersubject variability. To determine if SPEM changes meaningfully reflect clinical response, we are currently analyzing the correlation of SPEM findings with BPRS and SANS scores, as well as the heterogeneity of the responses. Further studies might explore the utility of SPEM as a potentially valuable and noninvasive tool for the monitoring of response to novel pharmacologic therapies for schizophrenia.